|Bid||11.780 x 1000|
|Ask||11.790 x 1800|
|Day's Range||11.620 - 11.835|
|52 Week Range||11.570 - 17.620|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.83|
Renderings reveal lab space, an atrium, a terrace, an office and cafe, along with outdoor seating and a kitchen.
In the second quarter, PTC Therapeutics generated revenues of $68.7 million—compared to $48.0 million in the second quarter of 2017, which reflected ~43% growth YoY (year-over-year). In the first half of 2018, PTC Therapeutics reported net revenues of $124.8 million—compared to $74.5 million in the first half of 2017.
On September 13, PTC Therapeutics’ stock price closed at $47.33, which is ~0.66% growth from the close of $47.02 the previous day.
The development, which spreads out over about 18 acres, would be a boost to the economy, creating 316 jobs in Orlando by Dec. 31, 2024, with an average annual wage of $69,670.
Audentes Therapeutics (BOLD) incurred a net loss of $31.37 million in the second quarter compared with a net loss of $22.74 million in the second quarter of 2017. That translates to a net loss per share of $0.85 in the second quarter of 2018. Its net loss per share was $0.87 in the second quarter of 2017.
In August, the FDA approved Amicus Therapeutics’ (FOLD) Galafold for the treatment of adults with a confirmed diagnosis of Fabry disease along with an amenable galactosidase alpha gene variant. The FDA’s approval of Galafold was according to the accelerated approval process based on the decrease in KIC GL-3 (kidney interstitial capillary cell globotriaosylceramide) substrate. Studies estimate that more than 3,000 individuals in the United States have Fabry disease.
On September 10, Amicus Therapeutics (FOLD) announced the regulatory and clinical progress of its AT-GAA development program for Pompe disease. The company has met with the FDA to discuss the regulatory trajectory for AT-GAA, and the FDA has provided final written minutes of the meeting. Amicus Therapeutics has implemented the suggestions of the FDA and the European Medicines Agency for the study.
CRANBURY, N.J., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the appointment of Lynn D. Bleil to its Board of Directors, effective immediately. Amicus also announced that current Director Michael G. Raab has been named Lead Independent Director.
NEW YORK, NY / ACCESSWIRE / September 10, 2018 / Wall Street plunged on Friday after the Trump administration announced tariffs on another $267 billion worth of Chinese goods, pressuring the S&P 500 and ...
During the third quarter, Amicus held a Type C meeting with the United States Food and Drug Administration (FDA) in order to discuss the regulatory path for AT-GAA. Specifically, Amicus sought input on the design of a pivotal study for full approval for AT-GAA, other supplemental clinical studies in Pompe disease patients, and whether Amicus may pursue an Accelerated Approval pathway in the United States at this time.
This southeast Orlando retail "shipping container" park will feature bars, restaurants and beach volleyball courts. Here are more details.
A global tech and biopharmaceutical will build a new facility in Lake Nona's life sciences hub if it decides to open a manufacturing plant. Cranbury, N.J.-based Amicus Therapeutics Inc. (Nasdaq: FOLD) is eyeing a site in Lake Nona's 650-acre Medical City, near the new Johnson & Johnson Human Performance Institute, for a proposed 190,690-square-foot facility, a spokeswoman with Lake Nona developer Tavistock Development Co., told Orlando Business Journal. Amicus is in talks with other cities for the facility, but Orlando City Council approved a nearly $380,000 incentive deal Aug. 20 to attract the company to Central Florida.
CRANBURY, N.J., Aug. 31, 2018-- Amicus Therapeutics today announced upcoming presentations at two investor conferences in September.. Bradley Campbell, President and Chief Operating Officer, and Chip Baird, ...
Orlando City Council approved a nearly $380,000 incentive deal Aug. 20 for a global tech and biopharmaceutical firm to build a major manufacturing plant in Lake Nona. Cranbury, N.J.-based Amicus Therapeutics Inc. (Nasdaq: FOLD) wants to build a 190,690-square-foot facility — its first biologic drug substance manufacturing plant with associated research and development in Lake Nona. The company will create 316 jobs in Orlando by Dec. 31, 2024.
Below is a list of notable corporate events for the week beginning August 13. Note, this list is not comprehensive and all dates are subject to change. All times are ET. View more earnings on NTAP Monday ...
Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.
Amicus Therapeutics on Monday set an average price of $315,000 per year for its newly approved Fabry disease treatment, a price it believes is below that of the main existing treatment in the United States. Galafold - approved on Friday by U.S. regulators - is the first new Fabry disease treatment in the country in over 15 years, and will compete with Sanofi SA's infused Fabrazyme, which has an average U.S. list price of $340,000 for adults, according to Amicus. Galafold is an oral therapy for Fabry disease, a sometimes fatal genetic condition in which accumulation of fat damages several organs.
The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) has experienced volatility amid the release of another spate of earnings reports. Even as the earnings season winds down, the upcoming week ...
U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs. Galafold, known chemically as migalastat, will be the first new Fabry treatment on the U.S. market in over 15 years, and will compete with Sanofi SA’s infused Fabrazyme. An estimated 3,000 people in the United States are diagnosed with the disease.
Amicus Therapeutics (FOLD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Galafold™ (migalastat) 123 mg capsules. Galafold is an oral, precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 0.00% and 12.65%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cranbury, New Jersey-based company said it had a loss of 33 cents per share. The results met Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...
2 Q18 Net Product Sales of $21.3 M Driven by Galafold ® Expansion. Company Increases FY18 Global Galafold Revenue Guidance to $80 M- $90 M. Pompe Clinical, Regulatory and Manufacturing Activities Continue ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Amicus Therapeutics, Inc. (NASDAQ: FOLD ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern ...
On Tuesday, Amicus Therapeutics (NASDAQ: FOLD ) will release its latest earnings report. Decipher the announcement with Benzinga's help. Earnings and Revenue Analysts are predicting Amicus Therapeutics ...